Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma
Journal of Gastroenterology · 2026
DOI: 10.1007/s00535-026-02343-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, 2026. Verfasst von Yosuke Uematsu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Hyaluronan Receptors, Pancreatic Neoplasms, Extracellular Vesicles. Die Arbeit nennt 55 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: CD44v6-positive extracellular vesicles (EVs) released by cancer cells drive tumor progression and liver metastasis. This study aimed to evaluate CD44v6-positive extracellular vesicles (EVs) as prognostic markers for pancreatic ductal adenocarcinoma (PDAC), a disease with poor prognosis. METHODS: Plasma samples from 100 patients with hepatobiliary and pancreatic diseases were retrospectively analyzed. Non-pancreatic and unresectable pancreatic cancer cases were included as control groups for cross-sectional comparisons, whereas prognostic analysis using preoperative plasma samples was limited to resected PDAC. EVs were defined based on CD9, CD63, and CD81 membrane antigens, and the proportion of CD44v6-positive EVs was measured using nano-flow cytometry. CD44v6 expression in resected PDAC tissues was assessed using immunohistochemistry. RESULTS: The proportion of CD44v6-positive EVs was significantly higher in patients with pancreatic cancer than in those without cancer (P = 0.0009). High CD44v6 expression in resected PDAC tissues correlated with elevated CD44v6-positive EVs in the plasma. Patients with CD44v6-positive EVs ≥ 31% had significantly poorer recurrence-free survival (P = 0.0008) and overall survival (P = 0.045) than those with < 31% EVs. Multivariate analysis confirmed CD44v6-positive EVs ≥ 31% were independent prognostic factors for recurrence-free (P = 0.005) and overall survival (P = 0.037), and a predictor of early liver metastasis (P = 0.001). CONCLUSIONS: These findings highlight the potential of preoperative quantification of CD44v6-positive EVs as a biomarker for risk stratification and treatment optimization in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan.
- Department of Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. dragonpegasus427@gmail.com.
- Department of Pathology, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan.
- Department of Pathology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan.
ORCID-Profile: Yosuke Uematsu
Zitieren
APA
Uematsu, Y., Matsuda, S., Kitago, M., Uemura, S., Shimane, G., Nakano, Y., Tanaka, M., Hori, S., Hasegawa, Y., Abe, Y., Masugi, Y., Takemura, R., & Kitagawa, Y. (2026). Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. Journal of Gastroenterology. https://doi.org/10.1007/s00535-026-02343-2
Vancouver
Uematsu Y, Matsuda S, Kitago M, Uemura S, Shimane G, Nakano Y, et al. Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. Journal of Gastroenterology. 2026. doi:10.1007/s00535-026-02343-2
BibTeX
@article{Uematsu2026,
author = {Uematsu, Yosuke and Matsuda, Sachiko and Kitago, Minoru and Uemura, Sho and Shimane, Gaku and Nakano, Yutaka and Tanaka, Masayuki and Hori, Shutaro and Hasegawa, Yasushi and Abe, Yuta and Masugi, Yohei and Takemura, Ryo and Kitagawa, Yuko},
title = {Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma},
journal = {Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s00535-026-02343-2}
}
EUVIMED